MX342537B - Proceso para la produccion de intermediarios de estetrol. - Google Patents
Proceso para la produccion de intermediarios de estetrol.Info
- Publication number
- MX342537B MX342537B MX2013014044A MX2013014044A MX342537B MX 342537 B MX342537 B MX 342537B MX 2013014044 A MX2013014044 A MX 2013014044A MX 2013014044 A MX2013014044 A MX 2013014044A MX 342537 B MX342537 B MX 342537B
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- compound
- group
- produce
- 4alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con un proceso para la preparación de un compuesto de fórmula (I), que comprende las etapas de: (a) hacer reaccionar un compuesto de fórmula (II), con un agente sililante o uno acilante para producir un compuesto de fórmula (III), en donde P1 es un grupo protector que se selecciona de R2Si-R3R4 o R1CO-, R1 es un grupo que se selecciona de alquilo de 1 a 6 átomos de carbono o cicloalquilo de 3 a 6 átomos de carbono, cada grupo está opcionalmente sustituido por uno o más sustituyentes que se seleccionan independientemente de fluoro o alquilo de 1 a 4 átomos de carbono; R2, R3 y R4 son cada uno independientemente un grupo que se selecciona de alquilo de 1 a 6 átomos de carbono o fenilo, cada grupo está opcionalmente sustituido por uno o más sustituyentes que se seleccionan independientemente de fluoro o alquilo de 1 a 4 átomos de carbono; b) halogenación o sulfinilación del compuesto de fórmula (III) para producir un compuesto de fórmula (IV); en donde X es halo, o -O-SO-R5 y R5 es un grupo que se selecciona de arilo de 6 a 10 átomos de carbono o heteroarilo, cada grupo está opcionalmente sustituido por uno o más sustituyentes que se seleccionan independientemente de cloro o alquilo de 1 a 4 átomos de carbono; c) deshalogenación o desulfinilación del compuesto de fórmula (IV) para producir el compuesto de fórmula (V); y d) hacer reaccionar el compuesto de fórmula (V) con un agente reductor para producir un compuesto de fórmula (I).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161492297P | 2011-06-01 | 2011-06-01 | |
EP11168560 | 2011-06-01 | ||
PCT/EP2012/060446 WO2012164095A1 (en) | 2011-06-01 | 2012-06-01 | Process for the production of estetrol intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014044A MX2013014044A (es) | 2014-08-21 |
MX342537B true MX342537B (es) | 2016-10-04 |
Family
ID=44588329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014044A MX342537B (es) | 2011-06-01 | 2012-06-01 | Proceso para la produccion de intermediarios de estetrol. |
Country Status (25)
Country | Link |
---|---|
US (1) | US11053273B2 (es) |
EP (1) | EP2714712B1 (es) |
JP (1) | JP6116550B2 (es) |
KR (1) | KR101957937B1 (es) |
CN (1) | CN103619867B (es) |
AU (1) | AU2012264601C1 (es) |
BR (1) | BR112013030833B1 (es) |
CA (1) | CA2835979C (es) |
CY (1) | CY1118164T1 (es) |
DK (1) | DK2714712T3 (es) |
EA (1) | EA025511B1 (es) |
ES (1) | ES2600703T3 (es) |
HR (1) | HRP20161369T1 (es) |
HU (1) | HUE031809T2 (es) |
LT (1) | LT2714712T (es) |
ME (1) | ME02585B (es) |
MX (1) | MX342537B (es) |
PL (1) | PL2714712T3 (es) |
PT (1) | PT2714712T (es) |
RS (1) | RS55293B1 (es) |
SG (1) | SG195121A1 (es) |
SI (1) | SI2714712T1 (es) |
SM (1) | SMT201600408B (es) |
WO (1) | WO2012164095A1 (es) |
ZA (1) | ZA201308445B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
WO2012164096A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
SG11201401282PA (en) | 2011-10-07 | 2014-05-29 | Estetra Sprl | Process for the production of estetrol |
TN2017000497A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
MA44205B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
MX2017016276A (es) | 2015-06-18 | 2018-06-19 | Mithra Pharmaceuticals S A | Unidad de dosificacion orodispersable que contiene un componente estetrol. |
LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
WO2023021026A1 (en) | 2021-08-17 | 2023-02-23 | Aspen Oss B.V. | A synthetic pathway to estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE144266C (es) | ||||
US3138588A (en) | 1962-08-24 | 1964-06-23 | American Home Prod | 17-ketals of estrone and derivatives thereof |
US3177206A (en) | 1963-03-07 | 1965-04-06 | American Home Prod | Selective bromination of a-ring aromatic 17-ketalized steroids |
US3433785A (en) | 1966-07-11 | 1969-03-18 | Sterling Drug Inc | 15,16-disubstituted aromatic steroids,intermediates and processes |
US3673180A (en) | 1970-06-18 | 1972-06-27 | Merck & Co Inc | 19-nor-6,6-ethylene-20-spiroxenes |
US4792620A (en) | 1983-10-14 | 1988-12-20 | Bp Chemicals Limited | Carbonylation catalysts |
US4739078A (en) | 1984-02-17 | 1988-04-19 | The Upjohn Company | Use of borohydride-salt lanthanide salt reagents for stereo selective reduction of C-15-keto prostaglandin precursors |
IE60780B1 (en) | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE3710728A1 (de) | 1987-03-31 | 1988-10-13 | Schering Ag | Verfahren zur herstellung von 17(alpha)-ethinyl-17ss-hydroxy-18-methyl-4,15-estradien-3-on und die neuen zwischenprodukte fuer dieses verfahren |
US5073374A (en) | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
JPH07101977A (ja) | 1993-10-05 | 1995-04-18 | Kureha Chem Ind Co Ltd | ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤 |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
TW548277B (en) * | 1999-07-16 | 2003-08-21 | Akzo Nobel Nv | Orally active androgens |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
US8048869B2 (en) | 2001-05-18 | 2011-11-01 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
PT1390042E (pt) | 2001-05-23 | 2008-03-10 | Pantarhei Bioscience Bv | Sistema de administração de um medicamento que compreende estrogénio tetrahidroxilado destinado à contracepção hormonal |
ATE449606T1 (de) | 2001-05-23 | 2009-12-15 | Pantarhei Bioscience Bv | Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption |
WO2003018026A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
EP1446128B1 (en) | 2001-11-15 | 2006-12-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
HU227198B1 (en) | 2001-11-27 | 2010-10-28 | Richter Gedeon Nyrt | Pharmaceutical composition for emergency contraception containing levonorgestrel |
CA2476940C (en) | 2002-02-21 | 2011-11-01 | Herman Jan Tijmen Coelingh Bennink | Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12 |
US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
US7943604B2 (en) | 2002-06-11 | 2011-05-17 | Pantarhei Bioscience B.V. | Method of treating human skin and a skin care composition for use in such a method |
CN1691947B (zh) | 2002-06-11 | 2011-11-23 | 潘塔希生物科学股份有限公司 | 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物 |
ATE382356T1 (de) | 2002-07-12 | 2008-01-15 | Pantarhei Bioscience Bv | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung |
DK1556058T3 (da) | 2002-10-23 | 2008-03-03 | Pantarhei Bioscience Bv | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi |
SI1562976T1 (sl) | 2002-11-08 | 2010-08-31 | Pantarhei Bioscience Bv | Sinteza estetrola preko steroidov, izvedenih iz estrona |
DK1624878T3 (da) | 2003-05-22 | 2007-01-08 | Pantarhei Bioscience Bv | Anvendelse af præparater som omfatter en östrogen komponent til behandling og forebyggelse af muskel-skelet-smerte |
RU2412196C2 (ru) | 2005-05-26 | 2011-02-20 | Зольвай Фармасьютиклз Гмбх | ИНГИБИТОРЫ 17β-ГСД1 И СТС |
JP5383189B2 (ja) | 2005-07-25 | 2014-01-08 | リボックス・ゲーエムベーハー | Rna依存性rnaポリメラーゼ、rnaを増幅するため及び/又は標識するための方法並びにキット |
US20070048369A1 (en) | 2005-08-26 | 2007-03-01 | National Starch And Chemical Investment Holding Corporation | Mucosal delivery tablet |
EP1971344B1 (en) | 2006-01-09 | 2010-09-22 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
SG174785A1 (en) | 2006-06-08 | 2011-10-28 | Warner Chilcott Co Llc | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
GB0621926D0 (en) | 2006-11-03 | 2006-12-13 | Medlock Medical Ltd | Multi directional stretch tubular bandages |
EP2086550A2 (en) | 2006-11-29 | 2009-08-12 | Wyeth | Estrogen/ serm and estrogen/ progestin bi-layer tablets |
US7867515B2 (en) | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
US8236785B2 (en) | 2007-01-08 | 2012-08-07 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
JP2010515758A (ja) | 2007-01-12 | 2010-05-13 | ワイス エルエルシー | 錠剤中錠剤組成物 |
CN102014924B (zh) | 2007-06-21 | 2012-07-18 | 潘塔希生物科学股份有限公司 | 用雌激素治疗胎粪吸入综合征 |
ES2376793T3 (es) | 2007-07-19 | 2012-03-16 | Pantarhei Bioscience B.V. | Tratamiento o prevención de trastornos hipertensivos del embarazo o retraso del crecimiento fetal |
ES2403203T3 (es) | 2007-08-31 | 2013-05-16 | National University Corporation Nagoya University | Método para producir compuesto carbonilo y prooxidante usado para la producción de compuesto carbonilo |
EP2077272A1 (en) | 2007-12-21 | 2009-07-08 | Affibody AB | Polypeptide libraries with a predetermined scaffold |
EP2077273B1 (en) | 2007-12-31 | 2011-09-14 | Animal Technology Institute Taiwan | Methods for separating casein from soluble proteins in a composition |
CN101318983A (zh) * | 2008-04-21 | 2008-12-10 | 上海大学 | 螺[(5β,6β,15β,16β-二亚甲基-雄甾-14β-氢-5,7-二烯-3-酮)-17α-2′-(1′-氧-环戊烷-5′-酮)]及其合成方法 |
WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
DE102009007771B4 (de) | 2009-02-05 | 2012-02-16 | Bayer Schering Pharma Aktiengesellschaft | Bukkales Applikationssystem, 17α-Estradiol enthaltend |
CN101560237A (zh) * | 2009-05-26 | 2009-10-21 | 上海大学 | 14β-氢-6β,7β,15β,16β-二亚甲基-3-氧代-17β-孕甾-4-烯-21,17-羧内酯及其合成方法 |
CN102058604A (zh) | 2009-11-17 | 2011-05-18 | 北京万全阳光医学技术有限公司 | 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法 |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
WO2012164096A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
HUE025350T2 (en) | 2011-07-19 | 2016-02-29 | Pantarhei Bioscience Bv | Tablets containing dehydroepiandrosterone (DHEA) |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
US9579329B2 (en) | 2011-08-11 | 2017-02-28 | Estetra S.P.R.L. | Use of estetrol as emergency contraceptive |
BR112014005134A2 (pt) | 2011-09-16 | 2017-04-18 | Ferring Bv | composição farmacêutica de dissolução rápida |
SG11201401282PA (en) | 2011-10-07 | 2014-05-29 | Estetra Sprl | Process for the production of estetrol |
EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
US9808470B2 (en) | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
WO2014159377A1 (en) | 2013-03-14 | 2014-10-02 | Teva Women's Health, Inc. | Compositions containing tanaproget and natural estrogens |
WO2015040051A1 (en) | 2013-09-18 | 2015-03-26 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
MA39105B1 (fr) | 2013-12-12 | 2018-05-31 | Donesta Bioscience B V | Unité de dosage solide se désintégrant par voie orale contenant un constituant estétrol |
MA44205B1 (fr) | 2015-06-18 | 2021-04-30 | Estetra Sprl | Comprimé orodispersible comprenant estetrol |
TN2017000497A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
MX2017016276A (es) | 2015-06-18 | 2018-06-19 | Mithra Pharmaceuticals S A | Unidad de dosificacion orodispersable que contiene un componente estetrol. |
-
2012
- 2012-06-01 PT PT127290534T patent/PT2714712T/pt unknown
- 2012-06-01 EP EP12729053.4A patent/EP2714712B1/en active Active
- 2012-06-01 DK DK12729053.4T patent/DK2714712T3/en active
- 2012-06-01 CA CA2835979A patent/CA2835979C/en active Active
- 2012-06-01 JP JP2014513213A patent/JP6116550B2/ja active Active
- 2012-06-01 ES ES12729053.4T patent/ES2600703T3/es active Active
- 2012-06-01 CN CN201280026131.6A patent/CN103619867B/zh active Active
- 2012-06-01 HU HUE12729053A patent/HUE031809T2/en unknown
- 2012-06-01 SG SG2013086715A patent/SG195121A1/en unknown
- 2012-06-01 LT LTEP12729053.4T patent/LT2714712T/lt unknown
- 2012-06-01 PL PL12729053T patent/PL2714712T3/pl unknown
- 2012-06-01 ME MEP-2016-253A patent/ME02585B/me unknown
- 2012-06-01 US US14/122,892 patent/US11053273B2/en active Active
- 2012-06-01 SI SI201230746A patent/SI2714712T1/sl unknown
- 2012-06-01 AU AU2012264601A patent/AU2012264601C1/en active Active
- 2012-06-01 KR KR1020137031484A patent/KR101957937B1/ko active IP Right Grant
- 2012-06-01 WO PCT/EP2012/060446 patent/WO2012164095A1/en active Application Filing
- 2012-06-01 BR BR112013030833A patent/BR112013030833B1/pt active IP Right Grant
- 2012-06-01 RS RS20160946A patent/RS55293B1/sr unknown
- 2012-06-01 EA EA201301315A patent/EA025511B1/ru unknown
- 2012-06-01 MX MX2013014044A patent/MX342537B/es active IP Right Grant
-
2013
- 2013-11-11 ZA ZA2013/08445A patent/ZA201308445B/en unknown
-
2016
- 2016-10-20 HR HRP20161369TT patent/HRP20161369T1/hr unknown
- 2016-10-26 CY CY20161101090T patent/CY1118164T1/el unknown
- 2016-11-10 SM SM201600408T patent/SMT201600408B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG195121A1 (en) | Process for the production of estetrol intermediates | |
SG195118A1 (en) | Process for the production of estetrol intermediates | |
MX348917B (es) | Proceso para la producción de estetrol. | |
PH12015500263A1 (en) | New bicyclic derivatives | |
PH12015500347A1 (en) | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
IN2013DE02977A (es) | ||
MX365744B (es) | Derivados de sulfuro de trifluoroetilo o sustituidos con n-arilamidina como acaricidas e insecticidas. | |
EA201500173A1 (ru) | Фунгицидные композиции | |
MX2014014531A (es) | Derivados de aminoquinazolina y piridopirimidina. | |
MY169267A (en) | New aryl-quinoline derivatives | |
MY172860A (en) | Dimethyl-benzoic acid compounds | |
MX2015017156A (es) | Inhibidores de bace. | |
MX2012008141A (es) | Compuestos y metodos. | |
MY169028A (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
IN2014DN00144A (es) | ||
WO2018091964A8 (en) | Process for preparing methoxy methyl pyridine dicarboxylate | |
TN2013000354A1 (en) | Synthesis of 2-carboxamide cycloamino urea derivatives | |
MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
IN2014MN00850A (es) | ||
MX2013000294A (es) | Intermedios y procedimiento de preparación de un inhibidor específico de la trombina. | |
IN2013DE02503A (es) | ||
IN2015DN02877A (es) | ||
MX342311B (es) | Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl). | |
IN2015DN02514A (es) | ||
MX344429B (es) | Nuevos compuestos de hexahidropirroloimidazolona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |